# Bioxytran, Inc. (BIXT)

> Healthcare · US · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/BIXT/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $ 0 | $ -2.17M | $ -554.6K | $ 855.0K | $ -2.59M |
| 2024 | $ 31.4K | $ -2.49M | $ -88.2K | $ 1.09M | $ -1.79M |
| 2023 | $ 0 | $ -4.59M | $ -886.3K | $ 1.93M | $ -2.43M |
| 2022 | $ 0 | $ -2.75M | $ -2.05M | $ 2.17M | $ -2.70M |
| 2021 | $ 0 | $ -4.16M | $ -2.06M | $ 2.12M | $ -2.76M |
| 2020 | $ 0 | $ -3.16M | $ -1.40M | $ 1.61M | $ -2.83M |
| 2019 | $ 0 | $ -2.40M | $ -556.4K | $ 851.0K | $ -799.3K |
| 2018 | $ 0 | $ -582.2K | $ -245.5K | $ 227.4K | $ -225.3K |
| 2017 | $ 257.4K | $ -488.4K | $ 16.8K | $ 110.0K | $ 542.4K |
| 2016 | $ 339.1K | $ -958.6K | $ -58.3K | $ 110.0K | $ -290.6K |
| 2015 | $ 359.2K | $ -2.95M | $ -3.8K | $ 110.0K | $ -195.2K |
| 2014 | $ 389.4K | $ -1.90M | $ -23.1K | $ 110.0K | $ -221.5K |
| 2013 | $ 593.6K | $ -2.53M | $ 4.7K | $ 121.0K | $ 75.4K |
| 2012 | $ 451.8K | $ -2.01M | $ -117.1K | $ 35.0K | $ 354.1K |
| 2011 | $ 112.1K | $ -3.46M | $ -819.1K | $ 35.0K | $ 163.3K |
| 2010 | $ 24.4K | $ -508.9K | $ -146.7K | $ 67.1K | $ -56.0K |
| 2009 | $ 0 | $ -419.2K | $ -306.6K | $ 94.5K | $ -100.5K |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | -0.33 |
| Liabilities / Eq | -1.25 |
| Current Ratio | 0.16 |

## Other views

- [Metrics](https://sponda.capital/en/BIXT.md)
- [Charts](https://sponda.capital/en/BIXT/charts.md)
- [Compare](https://sponda.capital/en/BIXT/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-27.